Biomarker exploration for SHR-1210 plus GEMOX as first-line treatment in advanced biliary tract cancer.
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2020.38.4_suppl.536
Abstract: 536Background: We conducted a trial to evaluate the efficacy and safety of SHR-1210 (a humanized anti-programmed cell death receptor 1 antibody) plus gemcitabine and oxaliplatin (GEMOX) as in untre... read more here.
Keywords: plus gemox; shr 1210; 1210 plus; exploration shr ... See more keywords